Affimed (AFMD)
(Delayed Data from NSDQ)
$3.69 USD
-0.27 (-6.82%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.70 +0.01 (0.27%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.69 USD
-0.27 (-6.82%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.70 +0.01 (0.27%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Zacks News
Affimed Appoints New CEO, Shares Fall on Leadership Change
by Zacks Equity Research
AFMD appoints Shawn M. Leland as the company's new chief executive officer. Stock falls on the news.
Oculis Holding AG (OCS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Oculis Holding AG (OCS) delivered earnings and revenue surprises of -30.23% and 3.21%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cyclacel Pharmaceuticals (CYCC) delivered earnings and revenue surprises of 13.25% and 86.67%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Affimed (AFMD) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Affimed's (AFMD) second-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline candidates being developed for various cancer indications.
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of -3.92% and 16.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Vanda (VNDA) Surges 24.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Vanda (VNDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study
by Zacks Equity Research
Affimed (AFMD) rallies 69% on positive follow-up efficacy data from its early to mid-stage study of the AFM24/Tecentriq combo therapy to treat heavily-pretreated EGFR wild-type NSCLC patients.
Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Affimed N.V. (AFMD) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Immatics (IMTX) delivered earnings and revenue surprises of 94.59% and 85.05%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Xenetic Biosciences (XBIO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 1.27% and 21.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Analyzing How You Should Play Cigna (CI) Ahead of Q1 Earnings
by Zacks Equity Research
The first-quarter results of Cigna (CI) are likely to reflect expanding commercial middle market memberships and growth in Cigna Healthcare profits.
Wall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 146.7% upside potential for Affimed N.V. (AFMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Affimed N.V. (AFMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Affimed N.V. (AFMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 263.4% upside potential for Affimed N.V. (AFMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Affimed N.V. (AFMD) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Affimed N.V. (AFMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seer, Inc. (SEER) delivered earnings and revenue surprises of 20% and 4.79%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 22.22% and 15.91%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Down -26.45% in 4 Weeks, Here's Why Affimed N.V. (AFMD) Looks Ripe for a Turnaround
by Zacks Equity Research
Affimed N.V. (AFMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Affimed N.V. (AFMD) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 0% and 68.68%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Inovio Pharmaceuticals (INO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inovio (INO) delivered earnings and revenue surprises of 7.14% and 13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -0.79% and 78.18%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of -2.50% and 29.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Affimed N.V. (AFMD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Affimed N.V. (AFMD) delivered earnings and revenue surprises of -4.55% and 26.95%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of -6.78% and 9.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics (CARA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of 7.55% and 22.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?